Corporate Symposia - CME
Tuesday, July 24 | 6 p.m. – 8 p.m.
Marriott Marquis Hotel, Great Lakes Ballroom ABCD
As several compounds targeting amyloid beta have failed to demonstrate a significant clinical and/or biomarker change, many aspects of the amyloid hypothesis are being reevaluated. These include the optimal timing for intervention, drug targets, patient population, potential need for multiple interventions (both upstream and downstream), and clinical trials’ design.
Jointly provided by Postgraduate Institute for Medicine and Miller Medical Communications, LLC.
This live activity is supported through an independent educational grant from Lilly.
Sponsored by: Lilly